|
| | Atenolol Chemical Properties |
| | Atenolol Usage And Synthesis |
| Pharmacological Affects | Atenolol ,also known as atenolol, Aten Yue Er, tamoxifen, downhill Ling blood pressure, Tenormin, blood pressure Ling, is a long-acting cardioselective β1-adrenergic blockers, without intrinsic sympathomimetic activity or membrane stability.The atenolol,s retardation for β1 adrenaline receptors is similar with metoprolol, propranolol and nadolol , which is 1/6 times for pindolol and timolol. But, it does not inhibit the effect of the isoproterenol bronchodilator.When administered in small doses, it does not like non-selective β-adrenergic blockers as aggravated hypoglycemia induced hypertensive crisis, peripheral circulatory impairment or patients with obstructive airways disease worsening airway function and so on. However, When administered in large doses, atenolol also can decrease asthma or chronic obstructive pulmonary disease, airway function. Atenolol, as a long-term treatment of hypertension, also were reported for affecting airway function. Thus, despite atenolol heart selection, chronic obstructive pulmonary disease patients can only use small doses, but also should be given a sufficient amount of β1-adrenergic receptor agonists.
Oral F is 46%~60%, Tmax about 2~4 h, Mainly unchanged since the urine excretion, T1/2 of 6~7 h. Hemodialysis can clear the goods. Rapidly absorbed from the gastrointestinal tract, but not exclusively.The rest of the body is excreted in the stool. Food can reduce the F, fasting and after meals AUC decreased by 20%. Distribution of the central nervous system is relatively few. The ratio of brain tissue to blood concentration was 0.1:1. Easy to achieve in the placenta and the maternal plasma concentrations of same. PPB is less than 5%, Vd is 50~75 L. Atenolol is not metabolized by the liver, most of the drug is excreted from the body in urine, renal insufficiency in patients with T1/2 was significantly prolonged. Patients with renal failure range of T1/2 was 10~28 h, or even up to 100 h. Results at 24 h after, the discharge from the urine of the drug can be reduced by 29%. The T1/2 of patients with hyperthyroidism was significantly shortened, 4.2h.
The above information is edited by the chemicalbook of Kui Ming.
| | Chemical Property | White powder. Melting point (146-148 ℃). Soluble in alcohol, slightly soluble in water, chloroform, Hardly soluble in ethyl ether, slightly smelly.
| | Uses | β-blockers. Clinical application in the treatment of hypertension, angina and arrhythmia.
| | Chemical Properties | White or almost white powder. | | Originator | Tenormin,Stuart,UK,1976 | | Uses | It is used for preventing angina pectoris. | | Uses | Selective b1 adrenergic receptor agonist, anti-hypertensive, anti-anginal, anti-arrhythmic | | Uses | Atenolol is 2-[4′[2-hydroxy-3-(iso-propylamino)propoxy]phenyl]acetamide
(12.1.7) [11–13].Atenolol is a selective β1-adrenoblocker, or in other words, a cardioblocker. Like acebutol,
atenolol possesses antianginal, antihypotensive, and antiarrhythmic action. It is used for arterial hypotension, preventing attacks of angina, sinus tachycardia, and preventing supraventricular tachyarrhythmia. | | Definition | ChEBI: An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent. | | Manufacturing Process | 1 gram of 1-p-carbamoylmethylphenoxy-2,3-epoxypropane and 10 ml of
isopropylamine in 25 ml of methanol is heated in a sealed tube at 110°C for
12 hours. The mixture is evaporated to dryness and the residue is partitioned
between 50 ml of chloroform and 50 ml of aqueous 2 N hydrochloric acid. The
aqueous acidic layer is separated, made alkaline with sodium carbonate and
extracted twice with 50 ml of chloroform each time. The combined extracts
are dried and evaporated to dryness and the residue is crystallized from ethyl
acetate. There is thus obtained 1-p-carbamoylmethyiphenoxy-3-
isopropylamino-2-propanol, MP 146-148°C.
The 1-p-carbamoylmethylphenoxy-2,3-epoxypropane used as starting material
may be obtained as follows: a mixture of 3.2 grams of phydroxyphenylacetamide,
25 ml of epichlorohydrin and 6 drops of piperidine is
heated at 95-100°C for 6 hours. The mixture is cooled and filtered and the
solid product is crystallized from methanol. There is thus obtained 1-pcarbamoylmethylphencxy-
2,3-epoxypropane, MP 158-160°C. | | Brand name | Tenormin (AstraZeneca). | | Therapeutic Function | Beta-adrenergic blocker | | General Description | Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards | | Biological Activity | Cardioselective β -adrenergic blocker. Antihypertensive, antianginal, antiarrhythmic. | | Biochem/physiol Actions | Selective β1-adrenoceptor antagonist; antihypertensive; antianginal; antiarrhythmic. | | Clinical Use | Beta-adrenoceptor blocker:
Hypertension
Angina
Arrhythmias | | Veterinary Drugs and Treatments | Atenolol may be useful in the treatment of supraventricular tachyarrhythmias,
premature ventricular contractions (PVC’s, VPC’s),
systemic hypertension and in treating cats with hypertrophic cardiomyopathy.
Atenolol is relatively safe to use in animals with bronchospastic
disease. | | in vitro | (r,s)-atenolol was found to differ slightly regarding potency and to be practically equal regarding relative selectivity, while ici 141,292 had slightly higher relative selectivity and much higher potency. (r,s)-atenolol exhibited highest affinity for the beta 1-receptor population. in contrast, ici 118,551 exhibited a very high relative selectivity with highest affinity for the beta 2-receptor subtype [1]. | | in vivo | the renal effects of (r,s)-atenolol in rats were studied. results showed that the iv infusion of (r,s)-atenolol increased urinary sodium excretion, urine volume (uv), urinary potassium excretion and urinary chloride excretion. (r,s)-atenolo intraaortally injected produced an increase in uv and sodium concentration in the urine, inducing a more marked increase in total sodium amount excreted from both kidneys [2]. | | Drug interactions | Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: NSAIDs antagonise hypotensive effect.
Anti-arrhythmics: increased risk of myocardial
depression and bradycardia; increased risk of
bradycardia, myocardial depression and AV block
with amiodarone; increased risk of myocardial
depression and bradycardia with flecainide.
Antidepressants: enhanced hypotensive effect with
MAOIs.
Antihypertensives: enhanced hypotensive effect;
increased risk of withdrawal hypertension with
clonidine; increased risk of first dose hypotensive
effect with post-synaptic alpha-blockers such as
prazosin.
Antimalarials: increased risk of bradycardia with
mefloquine.
Antipsychotics enhanced hypotensive effect with
phenothiazines.
Calcium-channel blockers: increased risk of
bradycardia and AV block with diltiazem;
hypotension and heart failure possible with
nifedipine and nisoldipine; asystole, severe
hypotension and heart failure with verapamil.
Cytotoxics: possible increased risk of bradycardia
with crizotinib.
Diuretics: enhanced hypotensive effect.
Fingolimod: possibly increased risk of bradycardia.
Moxisylyte: possible severe postural hypotension.
Sympathomimetics: severe hypertension with
adrenaline and noradrenaline and possibly with
dobutamine. | | Metabolism | Roughly half of an orally administered dose of
atenolol (Tenormin) is absorbed.The drug is eliminated
primarily by the kidney and unlike propranolol, undergoes
little hepatic metabolism. Its plasma half-life is approximately
6 hours, although if it is administered to a
patient with impaired renal function, its half-life can be
considerably prolonged. | | references | [1] golf, s. ,bjornerheim, r.,erichsen, a., et al. relative selectivity of different β-adrenoceptor antagonists for human heart β1- and β2-receptor subtypes assayed by a radioligand binding technique. scandinavian journal of clinical and laboratory investigation 47(7), 719-723 (1987).
[2] yamazaki n, monma y, tanabe t. effects of propranolol and atenolol on the rat kidney. nihon yakurigaku zasshi. 1983 may;81(5):333-42.
[3] stoschitzky k, egginger g, zernig g, klein w, lindner w. stereoselective features of (r)- and (s)-atenolol: clinical pharmacological, pharmacokinetic, and radioligand binding studies. chirality. 1993;5(1):15-9. |
| | Atenolol Preparation Products And Raw materials |
|
